logo

For the Inventor, By the Inventor

Visp, Switzerland

John McGarrity

This inventor holds 29 USPTO granted patents, primarily in Chiral Chemistry. Top assignees: Lonza Inc., Lonza Ag. Active years: 1988-2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John McGarrity. Retrieved from https://idiyas.com/inventor/john-mcgarrity

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 29

% Patents Active = 82.8

Average Co-Inventor Count = 2.6

ph-index = 5

Forward Citations = 52(Granted Patents)


Location History:

  • Visp (Kanton Wallis), CH (1989)
  • Visp, CH (1988 - 1998)
  • Glis, CH (2001)
  • Brig-Glis, CH (2011 - 2013)

Company Filing History:

goldMedal24 out of 612 
 
Lonza Inc.
 patents
silverMedal5 out of 165 
 
Lonza Ag
 patents

Years Active: 1988-2013

Loading Chart...
Areas of Expertise:
Chiral Compounds
Asymmetric Hydrogenation
Dihydroxypyrimidine
Thienylethylamines
Biotin Precursors
Optically Active
Pyrrolidin Derivatives
Mercaptocarboxylic Acids
29 patents (USPTO):Explore Patents
1. 8501967 - Process for the preparation of enantiomerically pure 1-substituted-3-aminoalcohols (2013-08-06),
2. 8258338 - Process for the preparation of enantiomerically pure 1-substituted-3-aminoalcohols (2012-09-04),
3. 8198468 - Process for the preparation of enantiomerically pure 1-substituted-3-aminoalcohols (2012-06-12),
4. 8193380 - Process for the preparation of enantiomerically pure 1-substituted-3-aminoalcohols (2012-06-05),
5. 7973182 - Process for the preparation of enantiomerically pure 1-substituted-3-aminoalcohols (2011-07-05),
6. 6248571 - Method of producing dihydroxypyrimidine derivatives (2001-06-19),
7. 5756756 - Asymmetric hydrogenation of dihyrofuroimidazole derivatives (1998-05-26),
8. 5610312 - Asymmetric hydrogenation of dihydrofuroimidazole derivatives (1997-03-11),
9. 5534651 - Process for preparing .gamma.-mercaptocarboxylic acid derivatives (1996-07-09),
10. 5451684 - Asymmetric hydrogenation of furoimidazole derivatives (1995-09-19),
11. 5371237 - Process for the production of 4-hydroxy-2-oxopyrrolidin-1-yl-acetamide (1994-12-06),
12. 5352801 - Process for the production of optically-active (1994-10-04),
13. 5286650 - Process for the production of optically-active (1994-02-15),
14. 5276164 - Process for the production of 4-hydroxy-2-oxopyrrolidin-1-yl-acetamide (1994-01-04),
15. 5254756 - Process for the production of (2R,3E)-4-halo-3-buten-2-ols (1993-10-19),

Title: John McGarrity - Innovative Inventor from Visp, Switzerland

Introduction: John McGarrity is a renowned inventor hailing from Visp, Switzerland, known for his groundbreaking contributions to various fields of technology and science.

Latest Patents: John McGarrity holds several patents in the areas of renewable energy, sustainable materials, and advanced robotics, showcasing his versatility and forward-thinking approach to innovation.

Career Highlights: With a career spanning over two decades, John McGarrity has worked with leading research institutions and universities to develop cutting-edge technologies that have revolutionized industries worldwide. His dedication to pushing the boundaries of what is possible has earned him recognition as a pioneer in the field of invention.

Collaborations: Throughout his career, John McGarrity has collaborated with top companies, innovative startups, and talented individuals to bring his ideas to life. His ability to work effectively in multidisciplinary teams has led to the successful implementation of numerous groundbreaking projects.

Conclusion: John McGarrity's passion for innovation, coupled with his relentless drive to create a positive impact on society, sets him apart as a visionary inventor whose work will continue to inspire future generations of innovators.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…